Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

Brief description of study

In this phase I pilot study, it is planned to investigate the feasibility and safety of
adding an interferon therapy to an preexisting imatinib treatment in patients with chronic
phase chronic myeloid leukaemia. The participating patients have already reached a response
during their imatinib therapy (CCyR) but have still a detectable disease (no molecular
response MR 4.5 or better).